Postpartum recurrence of Graves' hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy

Yoshinori Nakagawa, Kouki Mori, Saeko Hoshikawa, Makiko Yamamoto, Sadayoshi Ito, Katsumi Yoshida

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


OBJECTIVE: Previous studies recommend the discontinuation of antithyroid drug (ATD) therapy during pregnancy in women with well-controlled Graves' hyperthyroidism (GH). In this study, we investigated whether this termination of ATD therapy during pregnancy is beneficial in terms of postpartum GH recurrence. DESIGN: A nonrandomized, retrospective study. PATIENTS: Sixty-five pregnant GH patients treated with maintenance doses of ATDs were assigned into two groups: ATD therapy was discontinued before delivery in Group 1, but continued during pregnancy and after delivery in Group 2. MEASUREMENTS: The prevalence of postpartum recurrence or exacerbation of GH within 1 year after delivery was examined. Serum T4, T3 TSH, and TSH receptor antibody levels were measured. RESULTS: In Group 1, 70.8% (17/24) of patients suffered a recurrence of GH within 1 year after delivery. In contrast, a postpartum exacerbation of GH was observed in only 29% (12/41) of patients in Group 2 (P < 0.01). Both exacerbations and recurrences of GH appeared primarily within 4-6 months after delivery. Apparent neonatal hypothyroidism and malformations were not observed in the offspring of either group. CONCLUSION: Continuing antithyroid drug therapy throughout pregnancy prevents postpartum recurrence of Graves' hyperthyroidism without resulting in neonatal hypothyroidism or malformations.

Original languageEnglish
Pages (from-to)467-471
Number of pages5
JournalClinical Endocrinology
Issue number4
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Postpartum recurrence of Graves' hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy'. Together they form a unique fingerprint.

Cite this